FDA Approves 28 New Motiva Implant Sizes, Expanding U.S. Portfolio
ESTA sits 67% above its 52-week low of $38.38.
Summary
The FDA approved 28 additional sizes for Motiva SmoothSilk Round and Ergonomix breast implants, including volumes as low as 105 cc. This expands the U.S. portfolio across Mini, Demi, and Full profiles and will be commercially available before year-end. The approval directly supports the company's minimally invasive platform and addresses the growing demand for smaller, natural-looking augmentation. Management expects this to accelerate market share gains by giving surgeons a complete size range. This follows strong Q2 2026 results with revenue up 31.7% year-over-year and raised full-year guidance.
At the time of this announcement, ESTA was trading at $64.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $38.38 to $97.59. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.